GlassScriptPhysician profile
Sara Matani
NPI 1629481957
$2,509.03
in general payments reported to CMS, 2019-2025
30 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.20 · 2020: $23.22 · 2021: $117 · 2022: $424 · 2023: $598 · 2024: $659 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $24.04 · Entertainment: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.56 |
| Education | $24.04 |
| Entertainment | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $585.35 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $488.87 | 2021-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $363.78 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $98.34 | 2022-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $97.09 | 2022-2025 | |
| Abbvie INC. | $90.28 | 2024-2025 | |
| Horizon Therapeutics Plc | $88.32 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $78.97 | 2024 | |
| Lilly USA, LLC | $60.49 | 2022-2025 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $53.35 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $52.01 | 2025 | |
| Pfizer INC. | $47.97 | 2022-2024 | |
| Kyowa Kirin, INC. | $36.97 | 2023-2024 | Crysvita |
| Recordati_rare_diseases_inc. | $36.24 | 2024 | Signifor Lar, Isturisa |
| Merck Sharp & Dohme LLC | $34.68 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.82 | 2022-2023 | |
| Bolton Medical INC | $28.40 | 2024 | Treo Abdominal Stent-Graft System |
| Astrazeneca Pharmaceuticals LP | $27.62 | 2021 | |
| Abbott Laboratories | $26.87 | 2023 | Proclaim |
| Globus Medical, INC. | $22.71 | 2025 | Senza |
| Radius Health, INC. | $19.38 | 2025 | Tymlos |
| Alvogen INC | $18.45 | 2024 | Teriparatide |
| Optos, INC. | $17.84 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Xeris Pharmaceuticals, INC. | $17.69 | 2023 | Gvoke Hypopen |
| Echosens North America, INC. | $15.03 | 2024 | Fibroscan |
| Becton, Dickinson and Company | $14.93 | 2019 | |
| Antares Pharma, INC. | $14.58 | 2025 | Xyosted |
| Corcept Therapeutics | $14.27 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.22 | 2024 | Crysvita |
| Medtronic Minimed, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Matani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.